Background: Statins have recently been reported to cause a rare autoimmune inflammatory and/or necrotic myopathy that begins or persists after drug cessation. Methods: We report on 26 patients seen at a neuromuscular centre between 2005 and 2011 who demonstrated muscle weakness/myalgias and creatine kinase elevations during or after statin treatment with continuation of signs and symptoms despite statin withdrawal. Results: All patients were treated with immunosuppressive therapy with good response; all improved biochemically and 86% improved clinically. Sixty-five percent of patients who attempted to taper off immunosuppressive therapy relapsed. We report on a novel finding whereby five of the seven patients who underwent multiple biopsies throughout their disease demonstrated a transformation of their histological diagnosis, with four progressing from having myofibre necrosis with minimal or no inflammation to a diagnosis of polymyositis. Conclusions: This study offers preliminary evidence that statin-associated necrotizing myopathy and statin-associated polymyositis may not be separate entities but are part of the same pathophysiological spectrum. Both entities respond well to immunosuppression.
INTRODUCTION
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors, generically referred to as statins, lower cholesterol levels by reducing the synthesis of L-mevalonate, a crucial intermediate in the cholesterol biosynthesis pathway. Statins have been reported to be the most effective medications for controlling elevated concentrations of low-density lipoprotein cholesterol and to significantly lower the incidence of clinical cardiovascular endpoints. 1 As such, they are one of the most frequently prescribed drugs, with 21.6 million prescriptions in Canada in 2006 2 and 174 million in the United States in 2005. 3 In general, statin medications are well tolerated 4 ; however, clinical manifestations of statin-induced myotoxicity have been well described. [5] [6] [7] Muscle-related symptoms include myalgia (2%-22%), 7-10 muscle weakness (~3%), 9, [11] [12] [13] and life-threatening rhabdomyolysis (0.4 per 10,000 person-years), 14 which may occur months to years after statin initiation. These symptoms most often resolve completely upon cessation of the drug. 15 In contrast to these well-described clinical symptoms, the mechanisms proposed to explain acute statin myopathy are still elusive and theories include isoprenoid depletion, ubiquinone synthesis inhibition, sarcolemmal cholesterol alteration, and calcium metabolism perturbation. 16 More recently, reports have emerged of patients who developed myopathies during statin therapy that later persisted or even worsened despite statin discontinuation. Most such reports describe the development of three autoimmune myopathies: typical polymyositis (PM), [17] [18] [19] [20] typical dermatomyositis (DM), [21] [22] [23] [24] [25] [26] and an immune-mediated necrotizing myopathy (IMNM). 27, 28 These conditions will be herein referred to as statinassociated autoimmune myopathies (SAMs). Although inclusion body myositis (IBM) muscle biopsies show inflammation patterns similar to those of PM, 29 IBM is not included as a SAM because IBM patients have a distinct form of weakness and these patients do not maintain a response to immunosuppression. 30 Evidence also suggests IBM may be myodegenerative. 31 A previous study reported on potential mechanistic findings for one of the SAMs: statins increased expression of autoantibodies against HMGCR in patients with IMNM, and this prolongs the immune response as HMGCR becomes highly expressed in regenerating muscle fibres. 32 We completed a retrospective case series analysis to investigate the clinical, laboratory, and muscle biopsy findings of patients diagnosed with one of the SAMs. In addition to providing further clinical details about the SAM subgroups, we report that five of seven patients had changing histological diagnoses, namely, from IMNM to PM, with repeat biopsies. To our knowledge, this is the first study that demonstrates in multiple patients a biopsy-proven transformation with serial biopsies. Our findings suggest that PM and IMNM are part of a single pathophysiological spectrum as opposed to distinct entities. Further support for "lumping" comes from the fact that all SAM subgroups showed a good response to immunosuppression.
PATIENTS AND METHODS

Ethics Statement
The study protocol was approved by the Hamilton Health Sciences/Faculty of Health Sciences Research Ethics Board. The need for informed consent from participants was waived by the institutional review board (TCPS2 Article 2.2).
Data Collection
We retrospectively reviewed the medical records of all patients diagnosed at the McMaster University Neuromuscular and Neurometabolic Clinic between 2005 and 2011 with an autoimmune myopathy (i.e., PM, DM, IMNM, and nonspecific inflammatory myopathy [NSIM]) associated with statin therapy (i.e., current or discontinued within 6 months before initial visit). After investigation, all patients who remained on a statin had it discontinued by one of the investigators at the clinic (M.A.T. or S.K.B.). Records were taken from our database of clinical, biological, and pathological diagnoses of all patients who had a muscle biopsy and are monitored at the clinic.
A comprehensive collation of chronologically ordered information was extracted on the number, type(s), dosage(s), and duration(s) of statins or other lipid-lowering drugs (LLDs) used; indicators of myopathy (i.e., myalgias, weakness, dysphagia, rhabdomyolysis, renal dysfunction, hospitalization, hyperCKemia [elevated creatine kinase {CK} levels in blood]); findings from muscle biopsy, electromyography (EMG), and quantitative muscle strength tests; instances and consequences of rechallenge of a statin or other LLD; the use of concomitant drugs with pharmacologic interaction with statins or other myotoxic drugs, with the list of drugs cited in previous reviews, [33] [34] [35] conditions or behaviours that may predispose to statin-associated myopathy (i.e., mixed connective tissue disease, paraneoplastic syndromes, 27 obesity, hypothyroidism, hypertension, diabetes, alcohol use 34 ); serological markers of disease and inflammation (almost all cases were collected before the discovery of the anti-HMGCR antibody and serum samples were not stored for testing); and the outcomes of introducing and discontinuing immunosuppressive therapy.
Inclusion Criteria
After all available information was reviewed, only patients with probable SAMs were included. Inclusion criteria consisted of weakness, myalgia, and/or hyperCKemia (>220 IU/L in men; >170 IU/L in women) while on statin therapy. These clinical signs and symptoms had to persist or worsen for at least 2 months after discontinuing the statin and have indications for immunosuppressive therapy (i.e., prednisone, methylprednisolone, azathioprine, methotrexate, and/or intravenous immunoglobulin G [IVIgG]). Clinical tests conducted on all patients at the Neuromuscular Clinic included monopolar needle EMG, muscle biopsy, and knee extension (KE) strength test by quantitative isokinetic dynamometry (Biodex, Shirley, NY, USA) and Medical Research Council (MRC) muscle strength grading. Before treatment, all patients had abnormal EMG findings (fibrillations, positive sharp waves, and early recruiting motor unit action potentials). In addition, patients had to have a muscle biopsy that showed an inflammatory and/or necrotizing myopathy. Exclusion criteria included known muscular dystrophy; congenital, endocrine, or metabolic myopathy; or a preexisting inflammatory myopathy. A total of 26 patients met our inclusion/exclusion criteria for having a SAM during or after statin therapy.
Biopsy
Muscle biopsy samples were taken from the left or right vastus lateralis (N = 26), and if contraindicated (e.g., due to extreme atrophy), the right deltoid (N = 1). The biopsy was obtained using a Bergström needle, as described previously. 36 Muscle biopsy tissues were placed on a cork, rapidly frozen in liquid nitrogen, and stored at −85°C. Seven-micron-thick cryostat sections were routinely stained with hematoxylin and eosin (H&E), periodic acid-Schiff reaction, Oil Red O, and modified Gomori trichrome for assessment of morphology. A standard set of histochemical reactions was performed for the following enzymes: ATPase at pH 4.3, 4.5, and 10.0; alkaline and acid phosphatase; NADH; succinate dehydrogenase; myoadenylate deaminase; myophosphorylase; nonspecific esterase; and cytochrome c oxidase. 37 In all cases, biopsy material was cut to exhaustion, if required, until pathological changes were either detected or excluded. For identification of inflammatory cells, monoclonal antibodies against CD3 (Cell Marque, Rocklin, CA, USA), CD4 (Vector Laboratories, Burlingame, CA, USA), CD8, CD20, CD45, and CD68 (all from Daco, Carpenteria, CA, USA) were applied in recommended dilutions. Streptavidin-biotin detection system (Histostain Plus; Invitrogen, Grand Island, NY, USA) was used to visualize the immune reactions and followed by light hematoxylin counterstain.
Diagnosis
Clinical diagnostic criteria followed for PM and DM were based on those revised in a European Neuromuscular Centre Workshop in 2003, 38 themselves based on those initially set out by Bohan and Peter 39 in their seminal paper. Clinical diagnostic criteria for IMNM were from the same workshop.
In brief, these IMNM diagnostic criteria consisted of proximal weakness, hyperCKemia, EMG showing irritable membrane instability, and biopsy showing prominent necrotic muscle fibres with no or minimal inflammation (Figures 1a and 1b) . The histological criteria recommended by Hohlfeld 40 were followed for the differential diagnosis of inflammatory myopathies. The presence of T cells in direct contact with nonnecrotic muscle fibres was obligatory for the diagnosis of PM (Figures 2a  and 2b ). A diagnosis of DM was based on the perivascular distribution of inflammatory cells, almost exclusively CD20 + B cells with a few macrophages, with or without perifascicular atrophy. Biopsies with inflammatory infiltrates that did not strictly meet above requirements were designated as NSIM. All biopsies were reviewed twice by trained neuropathologists (B.L., J.P.P.) with more than 40 years of combined experiencefirst at initial diagnosis and again at data compilation following agreed-upon histological criteria and nomenclature for study purposes.
Analysis
To explore the hypothesis that statin-associated PM and IMNM are not completely separate entities but on the same pathophysiological spectrum, we compared characteristics of patients showing significant inflammation in the muscle biopsy (i.e., PM, NSIM) with patients diagnosed with IMNM ( Table 1 ). The interval data of the groups was compared using two-tailed Student's t test, and binary (yes-no) data were compared using Fisher's exact test (two-tailed p value). Significant differences between the groups are noted in "Results." We performed another analysis in which we compared incidence of SAM at our clinic with that in other epidemiological reports. The estimated incidence at our clinic was based on the assumption that we see about two-thirds of the 1.4 million residents in our catchment area. Finally, we analyzed exposure to statins between patients with SAM seen at our clinic with those in the general public. Data from the general public were retrieved from the "Health, United States, 2010" report from the National Center for Health Statistics. 41 Table 2 ) with patients who had a diagnosis of IMNM (patient nos. 1-8 in Table 2 ). Sum of the number of patients in both groups is not the total of 26 because patients with overlapping distinct diagnoses are not included in either group. 
RESULTS
We studied 26 patients, consisting of 17 men and 9 women. Their characteristics are summarized in Table 1 ; detailed casespecific data are shown in Tables 2a and 2b. The average age of onset was 66.4 years (range, 47-81 years). For SAM diagnoses; ten patients had PM, eight had IMNM, three had a NSIM, and five had changing inflammatory myopathy designations (i.e., these patients had more than one biopsy with different diagnoses). Risk factors associated with acute statin myopathies 42 were also associated with SAMs, including age, 43 hypothyroidism, diabetes mellitus type 2, previous surgery, and alcohol consumption (see Table 1 ). Table 1 summarizes the proportion of patients exposed to certain statins (which exceeds 100% because some patients were exposed to multiple statins). Average duration of treatment with statins before symptom onset was 72.4 months. In addition to statin exposure, eight patients had also taken ezetimibe, and one had taken cholestyramine as other LLDs. Six patients were concomitantly taking other drugs that amplify statin myotoxicity or interact with statin metabolism, namely, amiodarone, amlodipine, omeprazole, venlafaxine, and clarithromycin. Patients who concomitantly took these drugs had a paradoxically lower presenting CK (2,259 IU/L to 4,694 IU/L, p = 0.023) and a lower posttreatment CK (204 IU/L to 842 IU/L, p = 0.019). All patients were initially found to have hyperCKemia and weakness in at least one major muscle group. Also, males showed a higher peak CK (8,159 IU/L to 3,302 IU/L, p = 0.0088) and higher posttreatment CK (950 IU/L to 223 IU/L, p = 0.023) compared with females. Thirty-seven percent of patients showed some improvement after medication discontinuation (i.e., diminished myalgias and/or weakness and/or serum CK levels); however, all patients ultimately ended up with progressive or persisting symptoms of weakness, hyperCKemia, and/or myalgias. One patient also developed distal weakness, and 23% had to be hospitalized owing to severity of symptoms.
Average time off statins before an initial biopsy diagnosis of IMNM was 12.0 months, and for an initial biopsy diagnosis of PM/NSIM was 6.6 months (see Table 2a ). Seven patients underwent multiple biopsies: six with two biopsies and one with three biopsies. The reasons for repeat biopsies included deciphering the Figure 3 shows the first biopsy, which provided a diagnosis of IMNM, and Figures 4a and 4b show the second biopsy, performed 6 months later, which gave a diagnosis of PM. Five of these seven patients had subsequent biopsies in a different anatomical location from the first. Four of the five had changing histological diagnoses. All patients were treated with immunosuppressive therapy with a good response: lowering serum CK levels (100%) and improving or maintaining an MRC KE strength of at least 4+ (86%). Mean duration on immunosuppressive therapy at data collection was 23.4 months, with each patient taking an average of 2.2 immunosuppressive agents, including prednisone (96%), methotrexate (73%), azathioprine (19%), and IVIgG (35%). Fifteen patients tried to lower the immunosuppressant dose, of which ten patients relapsed and required a return to a higher dose, whereas five patients tapered to a lower dose of prednisone (2.5-5.0 mg) without relapse (see Table 2b ). On the basis of clinical need (hypercholesterolemia and risk factors), 10 of these 15 were rechallenged with other LLDs for a total of 19 rechallenge instances in this subgroup of those who tapered (some patients had more than one rechallenge). Within these 19 rechallenges, ten instances of adverse effects occurred: two of the three atorvastatin rechallenge instances, four of the six for rosuvastatin, one of the one for pravastatin, and two of the eight for ezetimibe (see Table 2b ). Adverse effects generally included worsening hyperCKemia, weakness, falls, and accelerated decline, as well as one instance each of dysphagia and stomach problems.
We also conducted another analysis to estimate incidence of inflammatory myopathies not necessarily associated with statins within our clinic's catchment area. We found 46 cases of inflammatory myopathy (PM, DM and nonspecific myositis) over the observation period (2005-2011), and we see around two-thirds of the patients with neuromuscular problems in our 1.4 million-resident catchment area, so we calculated an expected incidence rate of 7.0 cases per million patients per year. This finding is very close to other reports, which cite 5-10 44,45 and 2.2-8.8 46 cases of inflammatory myopathies per million per year. We further analyzed the rate of statin usage in our population of inflammatory myopathy cases (excluding IBM, because little evidence for its association with statins exists) and found that a greater than expected 69% of these patients during this time took a statin, compared with the 25% rate in the U.S. population in the same age group (aged 45 years and older), 41 further supporting that the association is more than coincidental. As expected, of our patients with IBM, only 20% were exposed to statins. Finally, in comparing statin-exposed patients that had inflammatory myopathy with statin-naïve patients, we observed two statistically significant differences: statin-naïve patients had lower pretreatment peak CK levels (2744 vs. 6451; p = 0.02) and were younger (53.2 vs. 66.1 years; p = 0.03).
DISCUSSION
This study offers important clinical information regarding diagnosis and treatment of patients with SAMs and provides data suggesting that statin-associated IMNM and PM may be related to the same pathophysiological mechanism and part of a diagnostic spectrum. Patients with statin-associated PM met established criteria for "idiopathic" PM in all aspects, implying that some proportion of "idiopathic" PM cases may have some identifiable trigger.
Because statins are one of the most frequently prescribed drugs, 2,3 we cannot exclude coincidence as the cause for the association between statin use and the observed myopathies. However, reports of immunomodulatory effects of statins are increasing, as are reports of the connection of this drug with other autoimmune diseases such as lupus and myasthenia gravis. 47, 48 We also found a higher rate of statin usage in our entire cohort of autoimmune myopathy patients-69% compared with 25% in the general public-which supports data from previous studies that reported rates of 47.6% 49 and 82% 27 of statin exposure in patients with inflammatory myopathy and IMNM, respectively. Finally, that 67% of all instances of statin rechallenge led to recurrence of signs and symptoms supports a true etiological association. Furthermore, several reports show that extended exposure to statins may induce the following: (1) increase of human leukocyte antigen class I expression by myocytes, 28 (2) chronic exposure of latent antigens after myocyte damage, and (3) promotion of a Th2type immune response as seen in "idiopathic" PM and DM. 50, 51 Within our sample of 26 SAM cases, we found several clinical associations. The observation of higher CKs (both peak and after treatment) in males was expected because males have greater muscle mass, show a greater inflammatory response to muscle damage, 52 and have higher CK levels in general. 53 Next, a paradoxical relationship was found where patients that concomitantly took drugs that amplify statin myotoxicity had lower presenting and posttreatment CK levels. These drugs would be expected to exacerbate acute statin-associated myotoxicity, and so in our case, this strengthens the likelihood that SAMs are not merely a persistence of acute drug-associated myotoxicity. Patients' sexes may also have confounded this finding: the group taking interacting drugs had a male:female ratio of 1:1, whereas the group that did not had a ratio of 2.2:1. No associations were observed between age and measured variables, including severity of disease, comorbidities, or treatment given.
Throughout the statin therapy, 25 instances of LLD rechallenge occurred. We found no association between whether the patient experienced adverse effects during LLD rechallenge versus age or sex. Comparing statins against other LLDs, we found that statins seem to have more severe and a higher risk of adverse effects. The other LLDs, ezetimibe, cholestyramine, and fenofibrate, seemed to be relatively better tolerated, with fewer and milder effects, consisting of hyperCKemia and fluctuating weakness. This finding is in agreement with a previous study on LLD rechallenge after acute statin-associated myotoxicity. 54 Patients who relapsed upon tapering immunosuppressive therapy were more likely to have had IVIgG therapy than those who did not relapse (73% to 17%, p = 0.0498). This outcome probably occurred because IVIgG was generally given to patients with more severe myopathy, and this association merely reflects that those with more severe disease were most likely to relapse upon tapering immunosuppressive therapy.
To investigate the hypothesis that IMNM is pathophysiologically related to PM, we tested the homogeneity of all measured factors between patients with IMNM and patients with significant inflammation on biopsy (i.e., PM and NSIM). The IMNM group showed more severe symptoms, consisting of lower posttreatment KE strength on the MRC scale (4.3 to 4.8, p = 0.038), as well as higher pretreatment CK (5,042 IU/L to 2,321 IU/L, p = 0.031). All other factors, including duration of statin treatment to onset, presenting symptoms, comorbidities, location of weakness, age, and sex were relatively homogenous between groups, offering preliminary evidence that the two groups do not represent distinct entities.
We hypothesize that IMNM and the statin-related inflammatory myopathies, PM and NSIM, are not separate entities but rather share a single pathophysiological spectrum. To reconcile the fact that not all statin-associated necrotizing myopathy patients develop inflammatory myopathy symptoms, we propose that a patient exposed to statins who develops myonecrosis may have either a myotoxicity that resolves upon statin cessation or an autoimmune IMNM that may transform to an inflammatory myopathy. The different outcomes may be due to distinct immune phenotypes of the patients. One might contend that the pathological alterations in muscle were a persistence of acute statin-associated myonecrosis; however, this assertion is implausible since the clinical, CK, and histological changes were seen long after statin cessation (89% had symptoms persisting even after the statin had been discontinued for >5 months). It would also not explain the flares that occurred when immunosuppressive therapies were tapered, nor the cases where the histology evolved toward greater inflammation (i.e., IMNM to PM transformation). Furthermore, attempts to taper off all immunosuppressive agents in all 26 patients led to clinical or biochemical (hyperCKemia) worsening. Collectively, the above data imply that statin exposure triggered a cascade of events leading to a perpetuating immunological disorder and not merely a circumscribed secondary inflammatory response to statin-induced myonecrosis. In this instance, other forms of toxic myopathies due to colchicine, amiodarone, ethanol, or highly active antiretrovirals, among many others, would be associated with dysimmune phenomena exaggerating the initial drug-induced myopathy, and they are not.
Two major concepts, which have supporting evidence from the literature, increase the plausibility of our hypothesis: (1) IMNM is caused by an immune-mediated mechanism just like PM, and (2) PM is a disease that can have various clinical and histopathological manifestations depending on time or location of biopsy. Three recent studies have described a total of 43 (10, 55 25, 27 and 8 28 ) patients who experienced persisting statin-associated IMNM. Researchers have reported associated inflammation in patients with IMNM, 56, 57 and another study showed five of 16 IMNM patients having endomysial and/or perivascular inflammatory cells. 55 Moreover, 42 of the 43 patients in the previously mentioned studies improved both symptomatically and serologically after treatment with glucocorticoid and immunosuppressive medication (one patient did not receive immunosuppressive therapy) (Mammen, A., personal communication, 2011), and of the patients in the previously mentioned studies, 15 of 18 relapsed after tapering of immunosuppressive therapy. Finally, preliminary mechanistic evidence shows IMNM to be immune mediated. Mammen et al. (2011) showed that statins upregulate expression of HMGCR, the major target of new autoantibodies in patients with statin-associated IMNM, and that these autoantibodies may prolong immune response despite statin discontinuation by targeting the HMGCR, which becomes highly expressed on regenerating muscle fibres. 32, 58 We recognize that anti-HMGCR autoantibody testing would have aided in characterization of histopathologic phenotypes; however, this test was not performed and is a limitation of this study. However, anti-HMGCR autoantibodies have not yet been proven to be pathogenic: up to 33% of patients positive for the antibodies were statin naïve. Moreover, 38 of 53 patients had necrotizing changes and 10 of 53 had prominent perivascular and endomysial inflammation, supporting our hypothesis of changing histopathology. Finally, the autoantibodies cannot explain why some patients develop a self-limited toxicity, whereas others develop a persistent IMNM since they are not expressed until after the necrotic insult has occurred.
Finally, the notion that PM is a "patchy" disease is important to interpret variable manifestations presenting over time and anatomical locations. For example, in many instances, PM is mentioned as being a patchy disease, 59 having patchy muscle involvement, 60, 61 or not having every abnormality presenting in every patient (i.e., clinical, histological, EMG, CK). 62 Such variation may be one reason for our findings of histopathologic transition from one diagnosis to another, since five patients had subsequent biopsies in a different anatomical location, four of whom had changing diagnoses. In fact, in a comprehensive review, 63 Dalakas states that misinterpretation of biopsies is the most common reason for misdiagnoses, especially those between sporadic IBM and PM, between PM or IMNM and inflammatory muscular dystrophies, and between PM and IMNM. This assertion supports the concept that the increasingly prevalent histopathologic diagnosis of IMNM is not necessarily an immutably distinct entity but rather a temporal (i.e., found intermittently within the time course of patients with PM) and/or spatial (i.e., "patchy") pathologic manifestation of an autoimmune myopathy spectrum.
This report links statins to the development of an autoimmune myopathy, with and without inflammatory findings, that persists or worsens even after statin withdrawal and responds to immunosuppressive therapy. Our data showing that poststatin myopathies can evolve into different histological diagnoses and yet still respond in a similar manner to the same disease-modifying agents increase the likelihood that statin-associated PM and IMNM are part of a single entity (i.e., can be lumped). Further studies, including the testing of anti-HMGCR autoantibodies in these patients, are needed. Because this test is now commercially available in Canada, it will further clarify this evolving area of neuromuscular medicine here. 64 
